Literature DB >> 27907978

Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive.

R Ayoub1, S T Page2, R S Swerdloff1, P Y Liu1, J K Amory2, A Leung1, L Hull1, D Blithe3, A Christy3, J H Chao2, W J Bremner2, C Wang1.   

Abstract

Dimethandrolone (DMA, 7α,11β-dimethyl-19-nortestosterone) has both androgenic and progestational activities, ideal properties for a male hormonal contraceptive. In vivo, dimethandrolone undecanoate (DMAU) is hydrolyzed to DMA. We showed previously that single oral doses of DMAU powder in capsule taken with food are well tolerated and effective at suppressing both LH and testosterone (T), but absorption was low. We compared the pharmacokinetics and pharmacodynamics of two new formulations of DMAU, in castor oil and in self-emulsifying drug delivery systems (SEDDS), with the previously tested powder formulation. DMAU was dosed orally in healthy adult male volunteers at two academic medical centers. For each formulation tested in this double-blind, placebo-controlled study, 10 men received single, escalating, oral doses of DMAU (100, 200, and 400 mg) and two subjects received placebo. All doses were evaluated for both fasting and with a high fat meal. All three formulations were well tolerated without clinically significant changes in vital signs, blood counts, or serum chemistries. For all formulations, DMA and DMAU showed higher maximum (p < 0.007) and average concentrations (p < 0.002) at the 400 mg dose, compared with the 200 mg dose. The powder formulation resulted in a lower conversion of DMAU to DMA (p = 0.027) compared with both castor oil and SEDDS formulations. DMAU in SEDDS given fasting resulted in higher serum DMA and DMAU concentrations compared to the other two formulations. Serum LH and sex hormone concentrations were suppressed by all formulations of 200 and 400 mg DMAU when administered with food, but only the SEDDS formulation was effectively suppressed serum T when given fasting. We conclude that while all three formulations of oral DMAU are effective and well tolerated when administered with food, DMAU in oil and SEDDS increased conversion to DMA, and SEDDS may have some effectiveness when given fasting. These properties might be advantageous for the application of DMAU as a male contraceptive.
© 2016 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  androgen; dimethandrolone; male contraception; pharmacokinetics; suppression of gonadotropins

Mesh:

Substances:

Year:  2016        PMID: 27907978      PMCID: PMC5352517          DOI: 10.1111/andr.12303

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   4.456


  26 in total

1.  Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits.

Authors:  Barbara J Attardi; Jean A Engbring; David Gropp; Sheri Ann Hild
Journal:  J Androl       Date:  2010-12-16

2.  7alpha,11beta-Dimethyl-19-nortestosterone: a potent and selective androgen response modulator with prostate-sparing properties.

Authors:  C Edgar Cook; John A Kepler
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

Review 3.  Acceptability of contraception for men: a review.

Authors:  Anna Glasier
Journal:  Contraception       Date:  2010-05-04       Impact factor: 3.375

Review 4.  Hormonal approaches to male contraception.

Authors:  Christina Wang; Ronald S Swerdloff
Journal:  Curr Opin Urol       Date:  2010-11       Impact factor: 2.309

5.  Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.

Authors:  Anthony Y Yin; Michelle Htun; Ronald S Swerdloff; Maruja Diaz-Arjonilla; Robert E Dudley; Sandra Faulkner; Rachelle Bross; Andrew Leung; Sima Baravarian; Laura Hull; James A Longstreth; Steven Kulback; Gregory Flippo; Christina Wang
Journal:  J Androl       Date:  2011-04-07

6.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

7.  Contraceptive efficacy of a depot progestin and androgen combination in men.

Authors:  Leo Turner; Ann J Conway; Mark Jimenez; Peter Y Liu; Elise Forbes; Robert I McLachlan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

Review 8.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

9.  Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs.

Authors:  David M Shackleford; W A Faassen; Natalie Houwing; Holger Lass; Glenn A Edwards; Christopher J H Porter; William N Charman
Journal:  J Pharmacol Exp Ther       Date:  2003-06-13       Impact factor: 4.030

Review 10.  Male Hormonal Contraception: Where Are We Now?

Authors:  Christina Wang; Mario P R Festin; Ronald S Swerdloff
Journal:  Curr Obstet Gynecol Rep       Date:  2016-01-29
View more
  14 in total

Review 1.  Estrogens and Body Weight Regulation in Men.

Authors:  Katya B Rubinow
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 2.  Testosterone Replacement Therapy in Hypogonadal Men.

Authors:  Christina Wang; Ronald S Swerdloff
Journal:  Endocrinol Metab Clin North Am       Date:  2022-02-08       Impact factor: 4.741

3.  Hormonal Male Contraception: Getting to Market.

Authors:  Stephanie T Page; Diana Blithe; Christina Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

Review 4.  Continuing the search for a hormonal male contraceptive.

Authors:  Fiona Yuen; Brian T Nguyen; Ronald S Swerdloff; Christina Wang
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-02-19       Impact factor: 5.237

5.  Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.

Authors:  Fiona Yuen; Arthi Thirumalai; Cindy Pham; Ronald S Swerdloff; Bradley D Anawalt; Peter Y Liu; John K Amory; William J Bremner; Clint Dart; Hongsheng Wu; Laura Hull; Diana L Blithe; Jill Long; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

6.  Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.

Authors:  Arthi Thirumalai; Jonas Ceponis; John K Amory; Ronald Swerdloff; Vijaya Surampudi; Peter Y Liu; William J Bremner; Eric Harvey; Diana L Blithe; Min S Lee; Laura Hull; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

Review 7.  Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.

Authors:  Jill E Long; Min S Lee; Diana L Blithe
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 8.  Emerging approaches to male contraception.

Authors:  Arthi Thirumalai; John K Amory
Journal:  Fertil Steril       Date:  2021-04-27       Impact factor: 7.490

9.  Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.

Authors:  Sherry Wu; Fiona Yuen; Ronald S Swerdloff; Youngju Pak; Arthi Thirumalai; Peter Y Liu; John K Amory; Feng Bai; Laura Hull; Diana L Blithe; Bradley D Anawalt; Toufan Parman; Kyuri Kim; Min S Lee; William J Bremner; Stephanie T Page; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2019-03-01       Impact factor: 6.134

10.  Accurate measurement of androgen after androgen esters: problems created by ex vivo esterase effects and LC-MS/MS interference.

Authors:  J Ceponis; R Swerdloff; A Leung; L Hull; F Bai; J Longstreth; R Dudley; T Danoff; C Wang
Journal:  Andrology       Date:  2018-10-21       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.